PubRank

F D Lublin

Author PubWeight™ 93.48‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 24.36
2 Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 4.27
3 Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011 4.25
4 Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008 3.28
5 Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 2008 2.29
6 The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007 2.17
7 Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996 1.64
8 Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology 2000 1.58
9 MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007 1.56
10 Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol 1996 1.55
11 Antibodies to GM1 and GD1b in patients with motor neuron disease without plasma cell dyscrasia. Ann Neurol 1989 1.55
12 A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 1997 1.54
13 Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology 2008 1.53
14 Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 2000 1.52
15 Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007 1.45
16 Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis. Arch Neurol 2001 1.40
17 Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 1994 1.27
18 Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler 2009 1.15
19 Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. Neurology 1999 1.12
20 Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology 1995 1.10
21 Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 2009 1.05
22 Delayed, relapsing experimental allergic encephalomyelitis in mice. J Immunol 1981 1.03
23 Acute experimental allergic encephalomyelitis in radiation bone marrow chimeras between high and low susceptible strains of mice. Immunogenetics 1986 0.97
24 Mitochondrial DNA mutations in multiple sclerosis. Mult Scler 1995 0.96
25 Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 1987 0.95
26 Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler 2010 0.94
27 The genetics of multiple sclerosis. A review. Biomed Pharmacother 1999 0.92
28 Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 1993 0.88
29 The sensitivity of the Mini-Mental State Exam in the white matter dementia of multiple sclerosis. J Clin Psychol 1992 0.88
30 Organ specific endothelial cell heterogeneity influences differential replication and cytopathogenicity of MHV-3 and MHV-4. Implications in viral tropism. Adv Exp Med Biol 1995 0.87
31 Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology 2006 0.85
32 Characterization of the mitochondrial DNA in patients with multiple sclerosis. J Neurol Sci 1996 0.84
33 Differential modulation of MHC class I antigen expression on mouse brain endothelial cells by MHV-4 infection. J Neuroimmunol 1989 0.83
34 Proof of concept studies for tissue-protective agents in multiple sclerosis. Mult Scler 2009 0.83
35 Relapsing experimental allergic encephalomyelitis. An autoimmune model of multiple sclerosis. Springer Semin Immunopathol 1985 0.83
36 Adoptive transfer of murine relapsing experimental allergic encephalomyelitis. Ann Neurol 1985 0.83
37 Mouse hepatitis virus (MHV-4, JHM) blocks gamma-interferon-induced major histocompatibility complex class II antigen expression on murine cerebral endothelial cells. J Neuroimmunol 1991 0.82
38 Syringoencephalomyelia (syringocephalus). J Neuropathol Exp Neurol 1981 0.82
39 Hydrocephalus in Kartagener's syndrome. Ear Nose Throat J 1986 0.82
40 Central nervous system and blood lymphocytes in experimental allergic encephalomyelitis. J Clin Lab Immunol 1983 0.82
41 Role of myelin antigens in murine relapsing experimental allergic encephalomyelitis. J Clin Lab Immunol 1984 0.82
42 Interferon-gamma-inducible endothelial cell class II major histocompatibility complex expression correlates with strain- and site-specific susceptibility to experimental allergic encephalomyelitis. J Neuroimmunol 1993 0.82
43 Relapsing experimental allergic encephalomyelitis in radiation bone marrow chimeras between high and low susceptible strains of mice. Clin Exp Immunol 1986 0.81
44 Delayed, relapsing experimental allergic encephalomyelitis in mice. Role of adjuvants and pertussis vaccine. J Neurol Sci 1983 0.81
45 Genetic regulation of susceptibility and severity of demyelination. Ann N Y Acad Sci 1988 0.81
46 Myokymia and impaired muscular relaxation with continuous motor unit activity. J Neurol Neurosurg Psychiatry 1979 0.80
47 Palliative care in patients with multiple sclerosis. Neurol Clin 2001 0.80
48 Effects of staphylococcal enterotoxin B on T cell receptor V beta utilization and clinical manifestations of experimental allergic encephalomyelitis. J Neuroimmunol 1993 0.80
49 Immunomodulation of relapsing experimental allergic encephalomyelitis. Neurology 1984 0.79
50 Screening for Leber's hereditary optic neuropathy associated mitochondrial DNA mutations in patients with prominent optic neuritis. Mult Scler 1997 0.79
51 Neuroimmunology: modulation of the hamster immune system by photoperiod. Life Sci 1987 0.79
52 Meningeal carcinomatosis complicating gynecologic malignancies: a literature review and report of a case. Obstet Gynecol Surv 1983 0.79
53 Lower extremity motor evoked potentials in multiple sclerosis. Arch Neurol 1991 0.79
54 Interleukin-6 induction in vitro in mouse brain endothelial cells and astrocytes by exposure to mouse hepatitis virus (MHV-4, JHM). J Neuroimmunol 1993 0.78
55 Trigeminal neuralgia in a patient with multiple sclerosis treated with high cervical spinal cord stimulation. Case report. Appl Neurophysiol 1988 0.78
56 Neuroendocrine regulation of immune parameters. Photoperiod control of the spleen in Syrian hamsters. Ann N Y Acad Sci 1988 0.78
57 Modulation of T cell-endothelial adhesion by astrocyte conditioned medium. Glia 1997 0.78
58 T cell receptor V beta gene utilization in myelin basic protein specific clones from CXJ1 recombinant inbred mice. J Neuroimmunol 1993 0.77
59 Regulation of MHC class I and II antigens on cerebral endothelial cells and astrocytes following MHV-4 infection. Adv Exp Med Biol 1990 0.77
60 Impairment of central and peripheral myelin in mitochondrial diseases. Mult Scler 1997 0.77
61 Clomiphene as an anticonvulsant drug: A case report. Arch Neurol 1982 0.77
62 Regulation of the expression of intercellular adhesion molecule-1 (ICAM-1) and the putative adhesion molecule Basigin on murine cerebral endothelial cells by MHV-4 (JHM). Adv Exp Med Biol 1993 0.76
63 A CD4-CDR3 peptide analog inhibits both primary and secondary autoreactive CD4+ T cell responses in experimental allergic encephalomyelitis. J Immunol 1996 0.75
64 Distribution of the blood-brain barrier in heterotopic brain transplants and its relationship to the lesions of EAE. J Neuropathol Exp Neurol 1992 0.75
65 Combination therapy for treatment of multiple sclerosis. Ann Neurol 1998 0.75
66 Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 2009 0.75
67 Characteristics of the T lymphocytes involved in experimental allergic encephalomyelitis. J Neuroimmunol 1995 0.75
68 Immune effects of intracerebral infection with mouse hepatitis virus. Ann N Y Acad Sci 1988 0.75
69 Down-regulation of interferon-gamma-induced class II expression on human glioma cells by recombinant interferon-beta: effects of dosage treatment schedule. J Neuroimmunol 1988 0.75
70 Clinical characteristics of progressive relapsing multiple sclerosis. Mult Scler 2004 0.75
71 The evolutionary relationship among Caucasian MS patients and controls. Mult Scler 1996 0.75
72 Generation of an anti-mouse brain endothelial cell monoclonal antibody that recognizes 84-110 kDa and 36 kDa determinants that are upregulated by cytokines. Adv Exp Med Biol 1993 0.75
73 The cellular response of JC virus T-antigen-induced brain tumor implants to a Murine intra-ocular model. J Neuroimmunol 2000 0.75
74 Down-regulation of gamma-interferon-induced class II expression of human glioma cells by recombinant beta-interferon. Ann N Y Acad Sci 1988 0.75
75 Reduced S-adenosylmethionine:protein-lysine N-methyltransferase activity (protein methylase III) in shiverer mutant mouse brain. Neurochem Res 1987 0.75
76 Immunopathogenic mechanisms in experimental allergic encephalomyelitis. Curr Opin Neurol Neurosurg 1993 0.75
77 Spectrum and classification of inflammatory demyelinating diseases of the central nervous system. Curr Neurol Neurosci Rep 2001 0.75
78 Heterotopic brain transplants in the study of experimental allergic encephalomyelitis. Exp Neurol 1987 0.75
79 Cytokine induction in vitro in mouse brain endothelial cells and astrocytes by exposure to mouse hepatitis virus (MHV-4, JHM). Adv Exp Med Biol 1993 0.75
80 Myelin basic protein-specific protein methylase I activity in shiverer mutant mouse brain. J Neurosci Res 1986 0.75
81 Separation and properties of lymphocytes obtained from the central nervous system. J Clin Lab Immunol 1980 0.75
82 Distributional patterns of multiple sclerosis brain lesions. Magnetic resonance imaging--clinical correlation. J Neuroimaging 1994 0.75
83 Preferential but not exclusive T cell receptor V beta chain utilization of myelin basic protein and peptide-specific T cell clones in mice. Cell Immunol 1994 0.75
84 Intracerebral beta-interferon in brain tumor therapy. Monitoring cerebral function with compressed spectral analysis. Ann N Y Acad Sci 1988 0.75